Satellos Bioscience Inc.
MSCL.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -17.45% | 67.32% | 24.33% | 3.09% | -470.38% |
| Gross Profit | 17.45% | -67.32% | -24.33% | -3.09% | 470.38% |
| SG&A Expenses | 30.63% | 50.19% | 45.70% | 12.49% | -14.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.70% | 61.24% | 30.12% | 5.73% | 23.61% |
| Operating Income | -34.70% | -61.24% | -30.12% | -5.73% | -23.61% |
| Income Before Tax | -62.59% | 12.41% | -26.04% | -18.48% | 7.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.89% | 12.12% | -26.76% | -19.71% | 7.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.89% | 12.12% | -26.76% | -19.71% | 7.23% |
| EBIT | -34.70% | -61.24% | -30.12% | -5.73% | -23.61% |
| EBITDA | -34.92% | -61.25% | -30.18% | -5.75% | -23.46% |
| EPS Basic | -6.40% | 40.65% | 16.51% | 18.58% | 13.15% |
| Normalized Basic EPS | -5.55% | -5.35% | 17.00% | 19.41% | 13.15% |
| EPS Diluted | -6.40% | 40.65% | 16.51% | 18.58% | 13.15% |
| Normalized Diluted EPS | -5.55% | -5.35% | 17.00% | 19.41% | 13.15% |
| Average Basic Shares Outstanding | 54.02% | 48.05% | 51.80% | 47.02% | 6.83% |
| Average Diluted Shares Outstanding | 54.02% | 48.05% | 51.80% | 47.02% | 6.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |